Navigation Links
Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary
Date:11/13/2007

of the webcast will be available on Isis' web site for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 18 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for a wide variety of diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.

This press release includes forward-looking statements regarding the development, activity, therapeutic potential and safety of mipomersen in treating patients with high cholesterol. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... DIEGO and CARDIFF-BY-THE-SEA, Calif. ... Inc. (NASDAQ: SRNE ;  Sorrento), an ... associated pain, and Conkwest, Inc., a privately-held immuno-oncology ... Natural Killer (NK) cell-line based therapy, announced today ... agreement to jointly develop next generation CAR-TNK™ (pronounced ...
(Date:12/19/2014)... Mass. , Dec. 18, 2014  Decision Resources ... the United States will increase to ... will be primarily driven by expansion in the large ... energy devices will be increasingly adopted due to the ... Other key findings from Decision Resources Group,s ...
(Date:12/19/2014)... , Dec. 18, 2014   Aratana ... a biopharmaceutical company focused on the licensing, development ... today announced positive results from its pivotal field ... for treating pain in dogs with osteoarthritis.  In ... pain assessment scores that were statistically significant compared ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5
... media event held today at the,Dello Russo Laser Vision ... and Jeffrey Dello Russo introduced the most advanced,eye laser ... Since Dr. Joseph Dello Russo introduced laser eye ... associated with the "firsts" in lasik evolution,leading the implementation ...
... Nov. 21 Alliance Pharmaceutical,Corp. (OTC Bulletin ... week in China with its partner Beijing ... its clinical development,plan for Oxygent(TM) (perfluorochemical [PFC] ... clinical development of Oxygent in China. The,clinical ...
Cached Medicine Technology:Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan 2
(Date:12/19/2014)... (PRWEB) December 19, 2014 Surviving Mesothelioma says ... EPA information indicates that these pipes can leach asbestos into ... to the full story on the Surviving Mesothelioma website. ... erosion of natural asbestos deposits, decaying water mains made of ... water. , To protect consumers from mesothelioma , ...
(Date:12/19/2014)... 2014 B. E. Smith, the only ... has been retained to lead a national chief ... in Estes Park, Colo. The top executive search firm ... placed more than 900 healthcare executives into organizations. ... not-for-profit critical access hospital and level IV trauma center, ...
(Date:12/19/2014)... Novellus Healthcare Communications, LLC announces ... Clinics™, an independent journal that provides practical information ... for patients inside the pharmacy and retail clinics. ... optimal access to quality care, Inside Patient Care: ... team treating and coordinating patient care in pharmacies ...
(Date:12/19/2014)... 2014 If you have ever been ... you probably wished you had an arsenal of treatments ... fibrosis, and other breathing disorders. Currently, the only proven ... triggers, but other common treatments do exist. At ... San Antonio, TX, 34 asthma educators responded to a ...
(Date:12/19/2014)... 2014 After a 13-year absence from ... returning to the stage to entertain his many worldwide ... performances, and the successful tour has been steadily expanding ... , Visit Ticketability.com for a large inventory ... at fair prices. , Music fans have had a ...
Breaking Medicine News(10 mins):Health News:Surviving Mesothelioma Warns of Potential Mesothelioma Risk from Cement Water Pipes 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 3Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 2Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 3Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 2Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 3Health News:Garth Brooks Tickets for Joe Louis Arena: Ticketability.com Becomes a Popular Destination for Discount Tickets for Garth Brooks’ Detroit Concerts Set for February 27-28 2
... Annual Meeting of SNM, the world's largest society ... German researchers stated that early metabolic imaging with ... to chemotherapy for esophageal cancer. ,"This ... from early metabolic response assessment to clinical decision ...
... Phase II studies of pazopanib in advanced or ... and soft tissue sarcoma (STS). These trials were ... American Society of Clinical Oncology (ASCO) in Chicago. ... support further investigations. ,Pazopanib is an ...
... as the earth endures, seedtime and harvest, cold and heat, summer ... ,- (Genesis 8:22, The Bible ). ,Our ... say, we, the people, of this planet earth, are to be ... our very existence. , ,Awareness ...
... already revealed that stress boosts the production of a ... study on mice has now shown that blocking a ... study, reported online in the Proceedings of the National ... of Medicine in St. Louis, is among the first ...
... tumor cell activity in women differs according to age, leading to ... ,Breast cancer tends to be more aggressive and less responsive ... and the study may lead to targeted therapies that can help ... by a team of researchers led by Carey Anders at the ...
... Duke University Medical Center has found that Flaxseed, an edible ... compounds known as lignans, is effective in halting prostate ... seed, which is similar to a sesame seed, may be ... to divide irregularly and become cancerous. ,The study, ...
Cached Medicine News:Health News:Esophageal Cancer Patients' Positive Responses to Chemotherapy Accurately Identified by PET 2Health News:Pazopanib Shows Positive in Advanced Renal Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 2Health News:Pazopanib Shows Positive in Advanced Renal Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 3Health News:Pazopanib Shows Positive in Advanced Renal Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 4Health News:World Environment Day (International Polar Year) 2Health News:World Environment Day (International Polar Year) 3Health News:World Environment Day (International Polar Year) 4Health News:Stress Protein Inactivation Cuts Alzheimer's Peptide in Mice 2Health News:Flaxseed Helps in Reducing the Risk of Prostate Tumor Spread 2
2L...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
... Pipette is a synonym for pipetting accuracy, ... design, and superior operating comfort. Its single, ... measuring stroke and blow-out as well as ... ensures utmost accuracy and precision. Ejection sleeve ...
5L...
Medicine Products: